ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BIAF
ISPC (30) ONMD (26) MXCT (34) NRC (67) ⌘ Pro Terminal →

bioAffinity Technologies Inc. (BIAF) — RQD Stock Rating Cockpit

$2.99 +2.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.00

bioAffinity Technologies Inc. (BIAF) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BIAF Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BIAF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, bioAffinity Technologies Inc. (NASDAQ: BIAF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.99 (+2.75% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BIAF compare to ISPC and ONMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), BIAF carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ISPC (iSpecimen Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BIAF?
▼

Per BIAF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001712762), bioAffinity Technologies Inc. generated $6.2M in revenue (-34.2% YoY), -$14.9M in net income, and -$9.4M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.00 (+0.30%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$85 Bull$3 Base$2 Bear
📬 FREE BIAF RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIAF)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY BIAF SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$3.63+0.8% Next Q
Q2 (-2Q)
34
Grade E$3.66-19.1% Next Q
Q3 (-1Q)
32
Grade E$2.96+1% Next Q
Current
29
Grade E$2.99-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BIAF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BIAF currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.04) and Max Pain ($3.14) forces dealer call-delta covering toward $84.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIAF• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BIAF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
34.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $3$2.99H: $81
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on BIAF

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

6/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like BIAF
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIAF)

  • ✓Walkthrough of BIAF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BIAF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.86%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.03H $3.03L $2.91C $2.99VOL 47.3K
RES: $27.00SUP: $2.40SMA50: $6.04SMA200: $19.07
$55.44$41.14$26.83$12.53$-1.78RES $27.00SUP $2.40$2.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIAF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BIAF Butterfly Map → + Track BIAF →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -34.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BIAF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BIAF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BIAF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIAF)

Health Care Rank #849 of 1015 ⚔️ ISPC vs BIAF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BIAF vs. ISPC, ONMD, MXCT, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, bioAffinity Technologies Inc. (BIAF) ranks #849 by composite RQD confidence (29/100, grade E) and #961 by equity capitalization ($3.7M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with BIAF at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BIAF ACTIVE
bioAffinity Technologies Inc.
E 29/100 — — -35.0% +2.75% $3.7M Benchmark Subject
ISPC
iSpecimen Inc.
E 30/100 — 11.2% -35.0% +0.82% $2.1M /ispc-vs-biaf →
ONMD
OneMedNet Corp (Class A)
E 26/100 — -30.0% -35.0% +1.42% $25.4M /onmd-vs-biaf →
MXCT
MaxCyte Inc.
E 34/100 — 96.0% -27.1% -8.80% $164.1M /mxct-vs-biaf →
NRC
NRC Health
C+ 67/100 44.8x — 21.0% +1.80% $527.1M /nrc-vs-biaf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001712762 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), bioAffinity Technologies Inc. (BIAF) reported GAAP revenue of $6.2M (-34.2% vs. FY2024 revenue of $9.4M , and +143.3% cumulative change since FY2023) , GAAP net income of -$14.9M, operating cash flow of -$9.3M, and free cash flow of -$9.4M (-27.9% YoY). On the balance sheet, BIAF closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.2M -$14.9M -$9.3M -$9.4M $11.0M —
FY2024 (FY) 2024-12-31 $9.4M -$9.0M -$7.3M -$7.3M $6.5M —
FY2023 (FY) 2023-12-31 $2.5M -$7.9M -$6.0M -$6.0M — —

3. BIAF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIAF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, bioAffinity Technologies Inc. (NASDAQ: BIAF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.99 (+2.75% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does BIAF compare to ISPC and ONMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), BIAF carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ISPC (iSpecimen Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BIAF?

Per BIAF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001712762), bioAffinity Technologies Inc. generated $6.2M in revenue (-34.2% YoY), -$14.9M in net income, and -$9.4M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BIAF trading relative to its 50-day, 200-day, and 52-week technical levels?

BIAF last traded at $2.99 (+2.75% on volume of 90,292 shares), positioning the stock -50.50% below its 50-day simple moving average ($6.04) and -84.32% below its 200-day simple moving average ($19.07). Across its 52-week range of $2.66 to $80.70, BIAF sits at the 0.4% percentile with a 14-day RSI of 34.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.62 to $3.36).

Direct Sub-Reports: BIAF RQD Cockpit BIAF 12M Forecast BIAF Earnings & Move BIAF Dividends & DRIP BIAF Insiders & 13F BIAF Whale Options BIAF Profit Sankey BIAF News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

BIAF — bioAffinity Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

bioAffinity Technologies Inc. (BIAF) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.99 (+2.75% 1D, market capitalization $3.7M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BioAffinity Technologies Inc. (BIAF) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. The source data identifies the company's sector, industry, and exchange, but does not describe its specific products, customers, or revenue model. Revenue is reported in the financial data (FY 2025: $6.2M; FY 2024: $9.4M; FY 2023: $2.5M), which indicates the company generates sales, though the sources do not detail how those sales are generated.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), bioAffinity Technologies Inc. (BIAF) reported $6.2M in annual revenue (up from $9.4M in FY2024, -34.2% YoY) and -$14.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, -$7.9M net income) through FY2025, BIAF scaled operating cash flow to -$9.3M and free cash flow to -$9.4M, backed by $11.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.66 – $80.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is Health Care / Biotechnology: Commercial Physical & Biological Resarch. The proprietary liquidity signal implies that BIAF's price sensitivity to net liquidity conditions is high (6.00x elasticity per the graph), meaning second-order moves in Fed balance-sheet and Treasury liquidity could amplify price swings in either direction. Investors should watch the financing cadence: a registered direct offering at market price, combined with negative free cash flow, creates a dilution pathway whose magnitude is not quantified in the source data.

  • Key Question #1: Can BIAF sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.2M and free cash flow of -$9.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BIAF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BIAF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for bioAffinity Technologies Inc. (BIAF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BIAF Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BIAF Bull vs. Bear Conversation Board — What's Your Call at $2.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BIAF 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BIAF:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $3.43 (+17.9%)
📌 Pinned Debate

A 94-severity bullish liquidity signal (96/100 Macro Tailwind Score, 6.00x net liquidity elasticity) indicates the stock is highly sens

Here is why I am bullish on BIAF here at $2.91: A 94-severity bullish liquidity signal (96/100 Macro Tailwind Score, 6.00x net liquidity elasticity) indicates the stock is highly sensitive to favorable Fed-TGA-RRP liquidity conditions.. Compare BIAF's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Commercial Physical & Biological Resarch. As long as cash conversion holds up, dips toward $2.76 are getting bought.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.91 and keeping dry powder in case we test $2.71.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.30 (-21.0%)
Spot @ $2.91

A 29/E RQD score with ROIC of -35%, a -60% operating margin, negative FCF of -$9.4M, and a 2/9 Piotroski F-Score indicates weak fundame

Sitting on the sidelines or leaning short BIAF above $2.91. A 29/E RQD score with ROIC of -35%, a -60% operating margin, negative FCF of -$9.4M, and a 2/9 Piotroski F-Score indicates weak fundamentals and forensic risk.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $80.70.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%